Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$44.88 USD
-1.65 (-3.55%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $44.89 +0.01 (0.02%) 7:40 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 38% (96 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.59 | 9.99 |
Current Quarter Estimate | -0.71 | -1.21 | 61.00 |
Year Ago Quarter Estimate | -0.99 | -0.07 | 54.84 |
Next Quarter Estimate | -0.74 | -1.90 | 63.00 |
Next Year Estimate | -3.07 | 12.55 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 25.06 | 19.70 | 15.67 |
Next Year | -3.72 | 15.20 | 11.34 |
Last 5 Years | NA | 7.00 | 8.10 |
Next 5 Years | NA | 22.60 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -3.96 |
Price/Book (MRQ) | 5.24 | 1.54 |
Price/Cash Flow (MRFY) | NA | 8.95 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | -61.35% |
Return on Equity (TTM) | -68.85% | -58.93% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.